209 related articles for article (PubMed ID: 22998776)
1. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.
Kleiman DA; Buitrago D; Crowley MJ; Beninato T; Veach AJ; Zanzonico PB; Jin M; Fahey TJ; Zarnegar R
J Surg Res; 2013 Jun; 182(1):85-93. PubMed ID: 22998776
[TBL] [Abstract][Full Text] [Related]
2. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma.
Wang ZF; Liu QJ; Liao SQ; Yang R; Ge T; He X; Tian CP; Liu W
Tumori; 2011; 97(4):540-6. PubMed ID: 21989446
[TBL] [Abstract][Full Text] [Related]
3. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
5. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
Cheng W; Liu R; Zhu G; Wang H; Xing M
J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
[TBL] [Abstract][Full Text] [Related]
7. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.
Orim F; Bychkov A; Shimamura M; Nakashima M; Ito M; Matsuse M; Kurashige T; Suzuki K; Saenko V; Nagayama Y; Yamashita S; Mitsutake N
Thyroid; 2014 Mar; 24(3):502-10. PubMed ID: 23924149
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
9. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
Franco AT; Malaguarnera R; Refetoff S; Liao XH; Lundsmith E; Kimura S; Pritchard C; Marais R; Davies TF; Weinstein LS; Chen M; Rosen N; Ghossein R; Knauf JA; Fagin JA
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1615-20. PubMed ID: 21220306
[TBL] [Abstract][Full Text] [Related]
10. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
[TBL] [Abstract][Full Text] [Related]
11. Expression of sodium/iodide transporters and thyroid stimulating hormone receptors in thyroid cancer patients and its correlation with iodine nutrition status and pathology.
Li J; Dong JN; Zhao Z; Lv Q; Yun B; Liu JQ; Cai XY
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4573-4580. PubMed ID: 30058701
[TBL] [Abstract][Full Text] [Related]
12. Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes.
Oler G; Nakabashi CD; Biscolla RP; Cerutti JM
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1313-6. PubMed ID: 19169486
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
[TBL] [Abstract][Full Text] [Related]
14. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
[TBL] [Abstract][Full Text] [Related]
15. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
[TBL] [Abstract][Full Text] [Related]
16. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
17. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.
Hoffmann S; Maschuw K; Hassan I; Wunderlich A; Lingelbach S; Ramaswamy A; Hofbauer LC; Zielke A
Endocrine; 2006 Aug; 30(1):129-38. PubMed ID: 17185801
[TBL] [Abstract][Full Text] [Related]
18. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
Zhang Z; Liu D; Murugan AK; Liu Z; Xing M
Endocr Relat Cancer; 2014 Apr; 21(2):161-73. PubMed ID: 24243688
[TBL] [Abstract][Full Text] [Related]
20. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.
So YK; Son YI; Baek CH; Jeong HS; Chung MK; Ko YH
Ann Surg Oncol; 2012 Mar; 19(3):990-5. PubMed ID: 21879263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
